GOUZE; Elvire

Patent Applications and Registrations

Patent applications and USPTO patent grants for GOUZE; Elvire.The latest application filed is for "hybrid promoters and their uses in therapy, notably for treating type ii collagenopathies".

Company Profile

6.3.13

GOUZE; Elvire - Nice FR
Gouze; Elvire - Vallauris FR
GOUZE; Elvire - Biot FR
GOUZE; Elvire - Nice Cedex 03 FR
Gouze; Elvire - Gainesville FL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Hybrid Promoters And Their Uses In Therapy, Notably For Treating Type Ii Collagenopathies App 20220290131 - GOUZE; Elvire	2022-09-15
Soluble Fibroblast Growth Factor Receptor 3 (sfgfr3) Polypeptides And Uses Thereof App 20210309718 - Gouze; Elvire ; et al.	2021-10-07
Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof Grant 11,021,528 - Gouze , et al. June 1, 2	2021-06-01
Soluble Fibroblast Growth Factor Receptor 3 (fgr3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders App 20210032608 - Gouze; Elvire	2021-02-04
Soluble Fibroblast Growth Factor Receptor 3 (fgr3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders App 20210032607 - Gouze; Elvire	2021-02-04
Soluble Fgfr3 Decoys For Treating Skeletal Growth Disorders App 20210009657 - Gouze; Elvire ; et al.	2021-01-14
Treatment Of Abnormal Visceral Fat Deposition Using Soluble Fibroblast Growth Factor Receptor 3 (sfgfr3) Polypeptides App 20200297799 - Gouze; Elvire ; et al.	2020-09-24
Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders Grant 10,724,014 - Gouze	2020-07-28
Soluble Fibroblast Growth Factor Receptor 3 (fgr3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retarda App 20200199545 - Gouze; Elvire	2020-06-25
Soluble Fibroblast Growth Factor Receptor 3 (sfgfr3) Polypeptides And Uses Thereof App 20200190162 - GOUZE; Elvire ; et al.	2020-06-18
Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof Grant 10,294,289 - Gouze , et al.	2019-05-21
Soluble Fibroblast Growth Factor Receptor 3 (sfgfr3) Polypeptides And Uses Thereof App 20180230197 - GOUZE; Elvire ; et al.	2018-08-16
Soluble Fgfr3 Decoys For Treating Skeletal Growth Disorders App 20180148494 - GOUZE; Elvire ; et al.	2018-05-31
A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders App 20150353624 - GOUZE; Elvire	2015-12-10
A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders App 20150344855 - GOUZE; Elvire	2015-12-03
Methods For Treating Articular Disease Or Dysfunction Using Self-complimentary Adeno-associated Viral Vectors App 20080187576 - Ghivizzani; Steven Craig ; et al.	2008-08-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.